

# David MacManus

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2827275/publications.pdf>

Version: 2024-02-01

14  
papers

705  
citations

1039406

9  
h-index

1281420

11  
g-index

14  
all docs

14  
docs citations

14  
times ranked

1122  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. <i>Lancet</i> , The, 2014, 383, 2213-2221.	6.3	361
2	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. <i>Lancet Neurology</i> , The, 2020, 19, 214-225.	4.9	81
3	Accuracy and precision in the measurement of relaxation times from nuclear magnetic resonance images. <i>British Journal of Radiology</i> , 1987, 60, 143-153.	1.0	53
4	Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. <i>Lancet Neurology</i> , The, 2021, 20, 709-720.	4.9	44
5	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. <i>BMJ Open</i> , 2018, 8, e021944.	0.8	43
6	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 429-440.	1.4	40
7	Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.5	31
8	A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 123-128.	0.9	25
9	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-72.	0.9	11
10	NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study. <i>American Journal of Neuroradiology</i> , 2020, 41, 2209-2218.	1.2	10
11	Lesion discrimination in optic neuritis using high-resolution fat-suppressed fast spin-echo MRI. <i>Neuroradiology</i> , 1996, 38, 317-321.	1.1	6
12	Accuracy and precision in the measurement of relaxation times from nuclear magnetic resonance images. <i>British Journal of Radiology</i> , 1987, 60, 1041-1042.	1.0	0
13	CANNABINOID USE IN PROGRESSIVE INFLAMMATORY BRAIN DISEASE (CUPID) MRI SUBâ€“STUDY. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, e2.93-e2.	0.9	0
14	Magnetic resonance imaging (MRI) of the orbit. <i>Radiography Today</i> , 1988, 54, 40-1.	0.0	0